Clinical features and disease severity of Turkish FMF children carrying E148Q mutation

Aydin F., Cakar N., Ozcakar Z. B. , Uncu N., Basaran O., Ozdel S., ...More

JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol.33, no.4, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1002/jcla.22852
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Keywords: E148Q, familial Mediterranean fever, MEFV mutation, pediatric, severity, FAMILIAL MEDITERRANEAN FEVER, GENOTYPE-PHENOTYPE, MEFV GENE, FREQUENCY, AMYLOIDOSIS


Background Familial Mediterranean fever (FMF) is the most common hereditary monogenic autoinflammatory disease caused by mutations in the MEFV gene. It is controversial whether E148Q alteration is an insignificant variant or a disease-causing mutation. The aim of this study was to evaluate the clinical features and disease severity of FMF patients carrying E148Q mutation. Methods Files of FMF patients were retrospectively evaluated. Patients with at least one E148Q mutation were included to the study. The clinical characteristics and disease severity of the patients who were carrying only E148Q mutation were compared with the patients who were compound heterozygous for E148Q and homozygous for M694V mutation. Results The study group comprised 33 patients who were homozygous or heterozygous for E148Q; 34 with compound heterozygous E148Q mutations and 86 patients who had homozygous M694V mutation. Patients who had only E148Q mutation were found to have the oldest mean age of disease onset and lowest mean disease severity score. Attack frequency and colchicine doses were lower in patients with only E148Q mutation as compared with the other two groups. The frequency of clinical findings such as fever, abdominal pain, arthralgia, and arthritis among the three groups was similar. Conclusion Familial Mediterranean fever patients with only E148Q mutation are presenting with late-onset and milder disease course despite having similar clinical findings as compared with patients who had other mutations. Finally, we imply that E148Q is a mutation and colchicine treatment should be given.